The text starts here.

News Release

FOR IMMEDIATE RELEASE
October 29, 2004

Eisai Announces Establishment of its Pharmaceuticals
Marketing Subsidiary in India

Eisai Co., Ltd. (Headquarters: Tokyo, President: Haruo Naito) announced that on October 27, 2004, it has established its pharmaceuticals marketing subsidiary, Eisai Pharmaceuticals India Private Ltd. in India.

In India, Eisai Pharmaceuticals India Private Ltd. will sell and promote pharmaceuticals developed by Eisai including ARICEPT (R), an Alzheimer's disease treatment, and Aciphex/Pariet(R), a proton pump inhibitor, and other pharmaceuticals.

The pharmaceutical market is growing rapidly in India, and we believe there is an opportunity to form a new base for pharmaceutical industries. In 2005, a system for drug substance patents will be established in India.

The newly established subsidiary company will establish a production-cost structure that enables the company to operate in the pharmaceutical market in India, and will provide a stable supply of quality products and appropriate product information for safe and proper usage to meet the medical needs of Indian patients.

[ Company Outline ]

Company Name:   Eisai Pharmaceuticals India Private Ltd.
Capital:   100 million rupees (approximately 240 million yen)
Location:   Mumbai, Maharashtra, India
Operations:   Application for pharmaceuticals registration, clinical research, commission of manufacture, promotion/sale of pharmaceuticals and import of drug materials
Form:   Private company

Contacts:

Eisai Co., Ltd.
Corporate Communications Department
Phone 03-3817-5120 (Tokyo)